Show simple item record

dc.contributor.authorMutlu, M.en_US
dc.contributor.authorRaza, U.en_US
dc.contributor.authorSaatci, Ö.en_US
dc.contributor.authorEyüpoğlu, E.en_US
dc.contributor.authorYurdusev, E.en_US
dc.contributor.authorŞahin, Ö.en_US
dc.date.accessioned2018-04-12T13:44:40Z
dc.date.available2018-04-12T13:44:40Z
dc.date.issued2016-06en_US
dc.identifier.issn0946-2716
dc.identifier.urihttp://hdl.handle.net/11693/38109
dc.description.abstractMicroRNAs (miRNAs) are 20–22-nucleotide small endogenous non-coding RNAs which regulate gene expression at post-transcriptional level. In the last two decades, identification of almost 2600 miRNAs in human and their potential to be modulated opened a new avenue to target almost all hallmarks of cancer. miRNAs have been classified as tumor suppressors or oncogenes depending on the phenotype they induce, the targets they modulate, and the tissue where they function. miR-200c, an illustrious tumor suppressor, is one of the highly studied miRNAs in terms of development, stemness, proliferation, epithelial-mesenchymal transition (EMT), therapy resistance, and metastasis. In this review, we first focus on the regulation of miR-200c expression and its role in regulating EMT in a ZEB1/E-cadherin axis-dependent and ZEB1/E-cadherin axis-independent manner. We then describe the role of miR-200c in therapy resistance in terms of multidrug resistance, chemoresistance, targeted therapy resistance, and radiotherapy resistance in various cancer types. We highlight the importance of miR-200c at the intersection of EMT and chemoresistance. Furthermore, we show how miR-200c coordinates several important signaling cascades such as TGF-β signaling, PI3K/Akt signaling, Notch signaling, VEGF signaling, and NF-κB signaling. Finally, we discuss miR-200c as a potential prognostic/diagnostic biomarker in several diseases, but mainly focusing on cancer and its potential application in future therapeutics.en_US
dc.language.isoEnglishen_US
dc.source.titleJournal of Molecular Medicineen_US
dc.relation.isversionofhttps://doi.org/10.1007/s00109-016-1420-5en_US
dc.subjectBiomarkeren_US
dc.subjectCell signalingen_US
dc.subjectDrug resistanceen_US
dc.subjectEpithelial-mesenchymal transition (EMT)en_US
dc.subjectmiR-200cen_US
dc.subjectTGF-βen_US
dc.subjectZEB1/2en_US
dc.subjectImmunoglobulin enhancer binding proteinen_US
dc.subjectMicroRNA 200cen_US
dc.subjectPhosphatidylinositol 3 kinaseen_US
dc.subjectTranscription factor ZEB1en_US
dc.subjectTransforming growth factor betaen_US
dc.subjectUvomorulinen_US
dc.subjectVasculotropinen_US
dc.subjectAntineoplastic agenten_US
dc.subjectCadherinen_US
dc.subjectCDH1 protein, humanen_US
dc.subjectMicroRNAen_US
dc.subjectMIRN200 microRNA, humanen_US
dc.subjectTranscription factor ZEB1en_US
dc.subjectTransforming growth factor betaen_US
dc.subjectZEB1 protein, humanen_US
dc.subjectZEB2 protein, humanen_US
dc.subjectZinc finger E box binding homeobox 2en_US
dc.subjectCancer growthen_US
dc.subjectCancer resistanceen_US
dc.subjectChemotherapy resistanceen_US
dc.subjectEpithelial mesenchymal transitionen_US
dc.subjectGene expressionen_US
dc.subjectGuard dogen_US
dc.subjectMultidrug resistanceen_US
dc.subjectNonhumanen_US
dc.subjectRadiotherapy resistanceen_US
dc.subjectReviewen_US
dc.subjectTherapy resistanceen_US
dc.subjectAnimalen_US
dc.subjectCell transformationen_US
dc.subjectDisease exacerbationen_US
dc.subjectDrug resistanceen_US
dc.subjectEpithelial mesenchymal transitionen_US
dc.subjectGene expression regulationen_US
dc.subjectGeneticsen_US
dc.subjectHumanen_US
dc.subjectMetabolismen_US
dc.subjectNeoplasmen_US
dc.subjectPathologyen_US
dc.subjectSignal transductionen_US
dc.subjectAnimalsen_US
dc.subjectAntineoplastic Agentsen_US
dc.subjectCadherinsen_US
dc.subjectCell Transformation, Neoplasticen_US
dc.subjectDisease Progressionen_US
dc.subjectDrug Resistance, Neoplasmen_US
dc.subjectEpithelial-Mesenchymal Transitionen_US
dc.subjectGene Expression Regulation, Neoplasticen_US
dc.subjectHumansen_US
dc.subjectMicroRNAsen_US
dc.subjectNeoplasmsen_US
dc.subjectSignal Transductionen_US
dc.subjectTransforming Growth Factor betaen_US
dc.subjectZinc Finger E-box Binding Homeobox 2en_US
dc.subjectZinc Finger E-box-Binding Homeobox 1en_US
dc.titlemiR-200c: a versatile watchdog in cancer progression, EMT, and drug resistanceen_US
dc.typeReviewen_US
dc.departmentDepartment of Molecular Biology and Genetics
dc.citation.spage629en_US
dc.citation.epage644en_US
dc.citation.volumeNumber94en_US
dc.citation.issueNumber6en_US
dc.identifier.doi10.1007/s00109-016-1420-5en_US
dc.publisherSpringer Verlagen_US


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record